- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07296744
Afgørende randomiseret undersøgelse af SUpira-systemet hos patienter, der gennemgår højrisiko perkutan koronar intervention (HRPCI) (SUPPORT II)
The objective of this study is to assess the safety and efficacy of the Supira System in providing temporary cardiovascular hemodynamic support in patients undergoing HRPCI. Eligible patients will be randomized to undergo HRPCI with either the Supira System (investigational device) or the commercially available Impella systems (comparator device).
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The Supira System is a minimally invasive percutaneous ventricular assist device (pVAD) that is intended to provide temporary hemodynamic support (≤ 4 hours) to patients undergoing HRPCI. The Supira Catheter is inserted percutaneously through the femoral artery, across the aortic valve, and into the left ventricle under fluoroscopic guidance, with the pump outlet remaining in the ascending aorta. The pump portion of the Catheter compresses during insertion in the Introducer Sheath and re-expands during use. It actively unloads the left ventricle by pumping blood from the ventricle into the ascending aorta and systemic circulation.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Supira Medical
- Telefonnummer: (669) 330-0883
- E-mail: clinical@supiramedical.com
Undersøgelse Kontakt Backup
- Navn: Chris DeMorett
Studiesteder
-
-
California
-
Loma Linda, California, Forenede Stater, 92354
- Rekruttering
- Loma Linda University Medical Center
-
Ledende efterforsker:
- VInoy Prasad, M.D.
-
Kontakt:
- Vinoy Prasad, M.D.
- Telefonnummer: 909-558-4200
- E-mail: khefflin@llu.edu
-
Sacramento, California, Forenede Stater, 95817
- Rekruttering
- UC Davis
-
Kontakt:
- Garrett Wong, M.D.
-
Ledende efterforsker:
- Garrett Wong, M.D.
-
Thousand Oaks, California, Forenede Stater, 91360
- Rekruttering
- Los Robles Regional Medical Center
-
Ledende efterforsker:
- Saibal Kar, M.D.
-
Kontakt:
- Saibal Kar, M.D.
- Telefonnummer: 805-852-9100
- E-mail: mane.arabyan@hcahealthcare.com
-
-
Florida
-
Miami, Florida, Forenede Stater, 33136
- Rekruttering
- University of Miami
-
Kontakt:
- Barbara Lang
- Telefonnummer: 305-243-4950
- E-mail: blang@med.miami.edu
-
Ledende efterforsker:
- Aditya Bharadwaj, M.D.
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- Rekruttering
- Emory University Hospital
-
Ledende efterforsker:
- Bill Nicholson, M.D.
-
Kontakt:
- Bill Nicholson, M.D.
- E-mail: wei.xu@emory.edu
-
Atlanta, Georgia, Forenede Stater, 30309
- Rekruttering
- Piedmont Heart Institute
-
Kontakt:
- David Kandzari, M.D.
-
Ledende efterforsker:
- David Kandzari, M.D.
-
Lawrenceville, Georgia, Forenede Stater, 30046
- Rekruttering
- Northside Hospital
-
Kontakt:
- Troy Crain
- Telefonnummer: 678-312-3828
- E-mail: Troy.Crain@northside.com
-
Ledende efterforsker:
- Michele Voeltz, M.D.
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Rekruttering
- Northwestern University
-
Kontakt:
- Joaquim Barboza, M.D.
- Telefonnummer: 312-664-3278
- E-mail: droshevs@nm.org
-
Ledende efterforsker:
- Joaquim Barboza, M.D.
-
-
Michigan
-
Detroit, Michigan, Forenede Stater, 48236
- Rekruttering
- Henry Ford Health / St. John Hospital
-
Kontakt:
- Amir Kaki, M.D.
-
Ledende efterforsker:
- Amir Kaki, M.D.
-
-
Minnesota
-
Saint Cloud, Minnesota, Forenede Stater, 56362
- Rekruttering
- CentraCare
-
Kontakt:
- Stephen Kidd, M.D.
-
Ledende efterforsker:
- Stephen Kidd, M.D.
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63110
- Rekruttering
- Washington University in St. Louis
-
Ledende efterforsker:
- John Lasala, M.D.
-
Kontakt:
- John Lasala, M.D.
- Telefonnummer: 314-362-1291
- E-mail: cjenifer@wustl.edu
-
-
New Jersey
-
Camden, New Jersey, Forenede Stater, 08103
- Rekruttering
- Virtua Health
-
Kontakt:
- Kristin Wade
- Telefonnummer: 856-355-1225
- E-mail: KMWADE@virtua.org
-
Ledende efterforsker:
- Kintur Sanghvi, M.D>
-
Paramus, New Jersey, Forenede Stater, 07652
- Rekruttering
- The Valley Hospital
-
Kontakt:
- Kimberly Michel
- Telefonnummer: 201-447-8453
- E-mail: KMICHEL@Valleyhealth.com
-
Ledende efterforsker:
- Raj Tayal, M.D.
-
-
New York
-
Buffalo, New York, Forenede Stater, 14203
- Rekruttering
- University of Buffalo (Buffalo General)
-
Ledende efterforsker:
- Vijay Iyer, M.D.
-
Kontakt:
- Vijay Iyer, M.D.
- Telefonnummer: 716-710-8266
- E-mail: ehejna@buffalo.edu
-
New York, New York, Forenede Stater, 10032
- Rekruttering
- Cuimc/Nyph
-
Kontakt:
- Megha Prasad, M.D.
-
Ledende efterforsker:
- Megha Prasad, M.D.
-
Underforsker:
- Ajay Kirtane, M.D.
-
The Bronx, New York, Forenede Stater, 10467
- Rekruttering
- Montefiore Medical Center
-
Kontakt:
- Andrea Mignatti, M.D.
-
Ledende efterforsker:
- Andrea Mignatti, M.D.
-
-
North Carolina
-
Asheville, North Carolina, Forenede Stater, 28803
- Rekruttering
- Mission Health
-
Kontakt:
- Josie Routhier
- Telefonnummer: 828-274-6001
- E-mail: Josephine.Routhier@HCAHealthcare.com
-
Ledende efterforsker:
- Michael Chenier, M.D.
-
-
Ohio
-
Columbus, Ohio, Forenede Stater, 43214
- Rekruttering
- OhioHealth
-
Ledende efterforsker:
- Arash Arshi, M.D.
-
Kontakt:
- Arash Arshi, M.D.
- Telefonnummer: 614-262-6772
- E-mail: joanna.flores-jones@ohiohealth.com
-
-
Oklahoma
-
Tulsa, Oklahoma, Forenede Stater, 74104
- Rekruttering
- Oklahoma Heart Hillcrest Medical
-
Ledende efterforsker:
- Kamran Muhammad, M.D.
-
Kontakt:
- Kamran Muhammad, M.D.
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97239
- Rekruttering
- OHSU
-
Kontakt:
- Firas Zahr, M.D.
- Telefonnummer: 503-494-1775
- E-mail: sampsonna@ohsu.edu
-
Ledende efterforsker:
- Firas Zahr, M.D.
-
Portland, Oregon, Forenede Stater, 97225
- Rekruttering
- Providence
-
Kontakt:
- Sheryl Ames
- Telefonnummer: 503-216-2099
- E-mail: Sheryl.Ames@providence.org
-
Ledende efterforsker:
- Kathryn Dawson, M.D.
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Rekruttering
- University of Pennsylvania
-
Kontakt:
- Joyce Wald, D.O.
- Telefonnummer: 215-615-4949
- E-mail: alyson.brown@pennmedicine.upenn.edu
-
Ledende efterforsker:
- Joyce Wald, D.O.
-
Ledende efterforsker:
- Jay Giri, M.D.
-
York, Pennsylvania, Forenede Stater, 17403
- Rekruttering
- Wellspan York Hospital
-
Ledende efterforsker:
- Rhian Davies, D.O.
-
Kontakt:
- Rhian Davies, D.O.
- Telefonnummer: 717-851-5153
- E-mail: hmckinney@wellspan.org
-
-
South Carolina
-
Columbia, South Carolina, Forenede Stater, 29203
- Rekruttering
- Prisma Health
-
Ledende efterforsker:
- Vince Vismara, M.D.
-
Kontakt:
- Vince Vismara, M.D.
- Telefonnummer: 803-434-3800
- E-mail: Suzanne.Smith@PrismaHealth.org
-
-
Texas
-
Plano, Texas, Forenede Stater, 75093
- Rekruttering
- Baylor Scott & White The Heart Hospital
-
Ledende efterforsker:
- Karim Al-Azizi, M.D.
-
Kontakt:
- Karim Al-Azizi, M.D.
- Telefonnummer: 469-800-6300
- E-mail: Osniel.GonzalezRamos@BSWHealth.org
-
-
Utah
-
Murray, Utah, Forenede Stater, 84107
- Rekruttering
- Intermountain Health
-
Kontakt:
- Savanna Chhak
- Telefonnummer: 801-507-4731
- E-mail: Savanna.Chhak@imail.org
-
Ledende efterforsker:
- Mitul Patel, M.D.
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Hemodynamically stable and will undergo elective or urgent (not emergent) HRPCI, where hemodynamic support is deemed necessary, as determined by the institutional Heart Team
- Informed consent granted by the subject or legally authorized representative
Exclusion Criteria:
- Cardiogenic shock or acutely decompensated pre-existing chronic heart failure
- Stroke within 6 months of the index procedure, or any prior stroke with permanent neurologic deficit
- Left ventricular thrombus
- Aortic and iliofemoral anatomical conditions that preclude safe delivery and placement of the investigational device or the comparator device
- Ongoing renal replacement therapy with dialysis
- Presence of decompensated liver disease; severe liver dysfunction
- Infection of the proposed procedural access site or active infection
- Known hypersensitivity to intravenous contrast agents that cannot be adequately pre-medicated or known hypersensitivity to heparin, aspirin, adenosine diphosphate (ADP) receptor inhibitors, or nitinol
- Any condition, coagulopathy, planned procedure or contraindication that requires discontinuation of antiplatelet and/or anticoagulant therapy within 90 days of the index procedure
- Breastfeeding or pregnant or planning to become pregnant within 90 days of the HRPCI procedure
- Currently participating in active follow-up phase of another clinical study of an investigational drug or device or planning to enroll in such a study within 90 days of the HRPCI procedure
- Other medical, social, or psychological problems that, in the opinion of the Investigator, compromises the subject's ability to provide written informed consent and/or to comply with study procedures
- Considered to be part of a vulnerable population per the investigator's assessment
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Supira System
Subjects receiving the Supira System |
The Supira System is a temporary (≤ 4 hours) ventricular support device indicated for use during elective or urgent HRPCI performed in hemodynamically stable patients with severe coronary artery disease when a heart team has determined HRPCI is the appropriate therapeutic option. |
|
Aktiv komparator: Impella
Subjects receiving the Impella |
The current commercially available Impella CP with SmartAssist Catheter is indicated for providing temporary (≤ 6 hours) ventricular support during elective or urgent high risk percutaneous coronary i |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Composite Safety and Efficacy Outcomes
Tidsramme: 30 days
|
|
30 days
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Secondary Outcome Measures
Tidsramme: 30 and 90 days
|
Individual rates of the following outcomes:
|
30 and 90 days
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CP-10004
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .